PSA Glycomics Assay for Early Detection of Prostate Cancer

Launched by PROF.DR. H.P. BEERLAGE · May 14, 2020

Keywords

ClinConnect Summary

This clinical trial is testing a new test called the PSA Glycomics Assay, which looks at urine and blood samples to help doctors understand the health of patients with higher levels of PSA, a substance that can indicate prostate problems. The main goals are to see if this test can accurately identify prostate cancer and determine how aggressive the cancer might be if present.

To participate in this study, men aged 65 to 74 who have a PSA level greater than 3 ng/mL can join, provided they can give informed consent. However, those who have bladder infections, are undergoing chemotherapy, are taking specific medications for prostate issues, or have other cancers or urological disorders cannot participate. For those who qualify, they will have their samples tested and may contribute to important research that could improve how prostate cancer is detected and treated in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with elevated PSA (\>3 ng/mL)
• • Signed informed consent
• Exclusion Criteria:
• • Patients that have a cystitis (bladder infection)
• • Patients under chemotherapy
• • Patients using 5-alpha reductase inhibitors
• • History or presence of cancers, or non-prostate urological disorders.